Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Melanoma | Research

Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis

Authors: Nan Wu, Hongyan Sun, Qian Sun, Fangqing Zhang, Lingli Ma, Yue Hu, Xianling Cong

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Recent studies have shown that circulating microRNAs (miRNAs) can be used as diagnostic biomarkers for melanoma. This study aimed to evaluate the diagnostic value of circulating miRNAs for melanoma.

Methods

A comprehensive literature search was conducted and the quality of the included literature was evaluated using QUADAS-2 (Quality Assessment for diagnostic accuracy studies), and the diagnostic accuracy was assessed by pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC). We used Deeks’ funnel plot to evaluate publication bias.

Results

The meta-analysis included 10 articles covering 16 studies, and the results showed that circulating miRNAs provide high diagnostic accuracy for melanoma. The overall pooled sensitivity was 0.87 (95% CI: 0.82–0.91), specificity was 0.81 (95% CI: 0.77–0.85), PLR was 4.6 (95% CI: 3.7–5.8), NLR was 0.16 (95% CI: 0.11–0.23), DOR was 29 (95% CI: 18–49), and AUC was 0.90 (95% CI: 0.87–0.92), respectively. Subgroup analysis showed better diagnostic value in miRNA clusters, European population, plasma miRNAs, and upregulated miRNAs compared to other subgroups.

Conclusions

The results indicated that circulating microRNAs can be used as a non-invasive biomarker for the diagnosis of melanoma.
Appendix
Available only for authorised users
Literature
1.
Singh SRK, Malapati SJ, Kumar R, et al. NCDB Analysis of Melanoma 2004–2015: epidemiology and outcomes by subtype, sociodemographic factors impacting clinical presentation, and Real-World Survival Benefit of Immunotherapy approval. Cancers (Basel). 2021;13(6).
2.
3.
Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet (London, England). 2018;392(10151):971–84.PubMedCrossRef
4.
Adams R, Coumbe JEM, Coumbe BT, et al. BRAF inhibitors and their immunological effects in malignant melanoma. Expert Rev Clin Immu. 2022.
5.
6.
7.
Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005–11.PubMed
8.
Glazer AM, Winkelmann RR, Farberg AS, et al. Analysis of Trends in US Melanoma incidence and mortality. Jama Dermatol. 2017;153(2):225–6.PubMedCrossRef
9.
10.
Kudchadkar RR, Lowe MC, Khan MK, et al. Metastatic melanoma. CA: a cancer journal for clinicians. 2020;70(2):78–85.PubMed
11.
Annovazzi A, Ferraresi V, Rea S, et al. Prognostic value of total metabolic tumour volume and therapy-response assessment by [F-18]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors (Nov, 10.1007/s00330-021-08355-1, 2021). Eur Radiol. 2022.
12.
Durante G, Broseghini E, Comito F, et al. Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer. Expert Rev Mol Diagn. 2022.
13.
Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. Nature Reviews Clinical Oncology. 2019;16(9):549–62.PubMedPubMedCentralCrossRef
14.
Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomolecular concepts. 2017;8(2):61–81.PubMedCrossRef
15.
Leão R, Albersen M, Looijenga LHJ, et al. Circulating MicroRNAs, the Next-Generation serum biomarkers in testicular germ cell tumours: a systematic review. European urology. 2021;80(4):456–66.PubMedCrossRef
16.
17.
Vychytilova-Faltejskova P, Slaby O. Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors. Experientia supplementum (2012). 2015;106:75–122.
18.
Huang Y, Chen Y, Tu S, et al. Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis. BMC infectious diseases. 2022;22(1):323.PubMedPubMedCentralCrossRef
19.
Ohtsuka M, Iwamoto K, Naito A, et al. Circulating MicroRNAs in Gastrointestinal Cancer. Cancers (Basel). 2021;13(13).
20.
Valihrach L, Androvic P, Kubista M. Circulating miRNA analysis for cancer diagnostics and therapy. Mol Aspects Med. 2020;72.
21.
Guo S, Guo W, Li S, et al. Serum miR-16: a potential biomarker for Predicting Melanoma Prognosis. The Journal of investigative dermatology. 2016;136(5):985–93.PubMedCrossRef
22.
Xu SJ, Xu WJ, Zeng Z, et al. MiR-424 functions as potential diagnostic and prognostic biomarker in Melanoma. Clin Lab. 2020;66(7):1207–13.
23.
Ross CL, Kaushik S, Valdes-Rodriguez R, et al. MicroRNAs in cutaneous melanoma: role as diagnostic and prognostic biomarkers. Journal of cellular physiology. 2018;233(7):5133–41.PubMedCrossRef
24.
Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as biomarkers in Disease: latest findings regarding their role in diagnosis and prognosis. Cells-Basel. 2020;9(2).
25.
26.
27.
Saldanha G, Potter L, Shendge P, et al. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma. The Journal of investigative dermatology. 2013;133(5):1381–4.PubMedCrossRef
28.
Ichigozaki Y, Fukushima S, Jinnin M, et al. Serum long non-coding RNA, snoRNA host gene 5 level as a new tumor marker of malignant melanoma. Exp Dermatol. 2016;25(1):67–9.PubMedCrossRef
29.
Armand-Labit V, Meyer N, Casanova A, et al. Identification of a circulating MicroRNA Profile as a biomarker of metastatic cutaneous melanoma. Acta Derm Venereol. 2016;96(1):29–34.PubMedCrossRef
30.
Kanemaru H, Fukushima S, Yamashita J, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61(3):187–93.PubMedCrossRef
31.
32.
Greenberg E, Besser MJ, Ben-Ami E, et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013;18(6):502–8.PubMedCrossRef
33.
34.
Fogli S, Polini B, Carpi S, et al. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol. 2017;39(5):1010428317701646.PubMedCrossRef
35.
Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br J Cancer. 2018;118(6):857–66.PubMedPubMedCentralCrossRef
36.
McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and Meta-analysis of Diagnostic Test Accuracy Studies: the PRISMA-DTA Statement. Jama. 2018;319(4):388–96.PubMedCrossRef
37.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–9.PubMedCrossRef
38.
Cohen JF, Deeks JJ, Hooft L, et al. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265.
39.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 2011;155(8):529–36.PubMedCrossRef
40.
Alegre E, Sanmamed MF, Rodriguez C, et al. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med. 2014;138(6):828–32.PubMedCrossRef
41.
Shiiyama R, Fukushima S, Jinnin M, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013;23(5):366–72.PubMedCrossRef
42.
Ono S, Oyama T, Lam S, et al. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015;6(9):7053–64.PubMedPubMedCentralCrossRef
43.
Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010;15(7):673–82.PubMedPubMedCentralCrossRef
44.
Margue C, Reinsbach S, Philippidou D, et al. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget. 2015;6(14):12110–27.PubMedPubMedCentralCrossRef
45.
Sabarimurugan S, Madurantakam Royam M, Das A, et al. Systematic review and Meta-analysis of the Prognostic significance of miRNAs in Melanoma Patients. Molecular diagnosis & therapy. 2018;22(6):653–69.CrossRef
46.
Varamo C, Occelli M, Vivenza D, et al. MicroRNAs role as potential biomarkers and key regulators in melanoma. Genes, chromosomes & cancer. 2017;56(1):3–10.CrossRef
47.
Guo Y, Zhang X, Wang L, et al. The plasma exosomal mir-1180-3p serves as a novel potential diagnostic marker for cutaneous melanoma. Cancer cell international. 2021;21(1):487.PubMedPubMedCentralCrossRef
48.
Tengda L, Shuping L, Mingli G, et al. Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res. 2018;28(4):295–303.PubMedCrossRef
49.
Bai M, Zhang H, Si L, et al. Upregulation of serum miR-10b is Associated with poor prognosis in patients with Melanoma. J Cancer. 2017;8(13):2487–91.PubMedPubMedCentralCrossRef
50.
51.
Stark MS, Klein K, Weide B, et al. The Prognostic and Predictive Value of Melanoma-related MicroRNAs using tissue and serum: a MicroRNA expression analysis. EBioMedicine. 2015;2(7):671–80.PubMedPubMedCentralCrossRef
52.
Yao ZF, Zhang XM, Wu Y. Preliminary study of serum specific miRNA for diagnosis of malignant melanoma. Journal of Clinical Dermatology. 2016;45(08):561–4.
53.
Li HF, Tang YZ, Tang JP, et al. Correlation between plasma miR-21 expression and clinicopathological characteristics in patients with Melanoma. Progress in Modern Biomedicine. 2020;20(23):4455–8.
54.
Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129–35.PubMedCrossRef
55.
Leiter U, Keim U, Garbe C. Epidemiology of skin Cancer: Update 2019. Adv Exp Med Biol. 2020;1268:123–39.PubMedCrossRef
56.
Tang KY, Zhang HL, Li YQ, et al. Circular RNA as a potential biomarker for Melanoma: a systematic review. Front Cell Dev Biol. 2021;9:14.
57.
Vlasov VV, Rykova E, Ponomareva AA, et al. [Circulating microRNAs in lung cancer: prospects for diagnostics, prognosis and prediction of antitumor treatment efficiency]. Mol Biol (Mosk). 2015;49(1):55–66.PubMed
58.
Ono S, Lam S, Nagahara M, et al. Circulating microRNA biomarkers as Liquid Biopsy for Cancer Patients: pros and cons of current assays. J Clin Med. 2015;4(10):1890–907.PubMedPubMedCentralCrossRef
Metadata
Title
Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis
Authors
Nan Wu
Hongyan Sun
Qian Sun
Fangqing Zhang
Lingli Ma
Yue Hu
Xianling Cong
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10891-6

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Study Protocol

HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial

Research

Construction of a comprehensive predictive model for axillary lymph node metastasis in breast cancer: a retrospective study

Research

Assessing cancer in people with profound and multiple disabilities

Research

Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases

Research

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

Research

A nomogram for predicting lateral lymph node metastasis in cN0 unifocal papillary thyroid microcarcinoma

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits